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Innovations
Polymerix Corporation:
Polymer Drugs for Device and Injection
“The original discovery that Kath- program, centered on the off-patent
NSAID, diflunisal. “Diflunisal is moreerine Uhrich made in her laboratory
potent than salicylic acid, more lipo-was to develop a polymer of salicylic
“The medical community has been
looking for ways to control the re-
lease of drugs in coated medical de-
vices and in targeted therapies for philic, so it likes tissue better, and itsacid, or aspirin,” explains Letton.
many applications,” says Alan Let- half-life in tissue is longer,” says“Her goal was to create a polymer
ton, PhD, Executive Vice President, Letton.that would degrade, but its byprod-
Research, at Piscataway, NJ-based “There are several advantages toucts would not be harmful and pos-
Polymerix Corporation. “This re- our approach over current systems,”sibly therapeutic. Salicylic acid does
quires two things: creating a drug as says Letton. Coated coronarythat.” Traditionally, as polymers de-
site-specific as possible and deliv- stents, for example, such as the re-grade in vivo, they can be highly in-
ering it at fairly high concentrations cently introduced sirolimus-coatedflammatory, requiring systemic ther-
in a controlled manner.” The goal stents, involve a permanent polymerapy. “PolyAspirin, as we call this
of the 15-person team at Polymerix coated onto the device. “But aftermaterial, is a polymer,” explains Vic-
is to fulfill these goals through the drug has done its thing, the poly-toria Hazelwood, Director, Business
the development of PolymerDrugs— mer is still sticking around on theDevelopment at Polymerix. “It is
drugs as the main component in a metal stent,” explains Letton, whichcomprised of salicylic acid linked
polymer backbone. “There are many can lead to what design engineerswith units of a benign natural metab-
ways people have tried to improve call inductance mismatch. He ex-olite, resulting in aspirin in a bio-
controlled drug release,” says Let- plains that with two dissimilar mate-degradable polymer form.” Initial
ton, “including use of an existing rials, one soft and one hard, as inanimal studies confirm that Poly-
polymer, biodegradable or not, the current coated stents, the likeli-Aspirin membranes reduce swelling
loaded with a drug that is specific for hood of those materials separatingand inflammation at the site of im-
that disease and injected or placed over time under load and stress isplantation.
next to the target site. In this case, very high. In the current stent de-
you are usually limited to how much sign, the polymer has a modulus that
drug you can attach to the polymer. is orders or magnitude less than that
“If you can make theBut if you can make the whole poly- of the steel. “The likelihood of de-
lamination leading to inflammatorymer out of the drug, it is a perfect whole polymer out of the
solution. This is what we do.” problems long-term is high, sincedrug, it is a perfect solu-
Therefore, PolymerDrugs are two the polymer is a permanent mate-
tion. This is what we do.”things: a delivery vehicle and a ther- rial,” he says. “The industry accepts
this complication now because itapeutic molecule. “Our polymers are –Alan Letton, PhD, Exec-
really a therapeutic carrier,” summa- delivers such a nice benefit with theutive VP, Research,
rizes Letton. “They can be used drug.” But Polymerix has developed
Polymerixalone as a therapeutic molecule or its polymer materials to be degrad-
admixed with other active drugs de- able. “Because the drug is the poly-
signed to be released as the polymer mer, as the drug is released, the
PolyNSAID-Coateddegrades in vivo,” he says. polymer is released simultaneously,”
Medical DevicesRutgers Foundation he says. Alternatively, if the polymer
The body’s response to any insult—The founding science behind Poly- is admixed with another drug, wherein
whether an injury, organic disease,merix was created in the laboratory it becomes a therapeutic carrier for
or implantation of a medical de-of Kathryn E. Uhrich, PhD, Associate that drug, “we can control release of
vice—leads to a cascade of eventsProfessor of Chemistry at Rutgers the drug as well,” explains Letton.
including inflammation and pain.University and Polymerix scientific The company has already studied
“The idea is to manage the inflam-cofounder. Her work has focused on such mixtures with sirolimus and
mation, pain, and scarring,” saysthe synthesis and characterization paclitaxel, respectively.
Letton. Dr. Uhrich started the pro-of biocompatible polymers for medi- “For a polymer drug used in inter-
cess through creation of PolyAspirincal and dental applications. The ventional vascular stent applica-
with potential application as a coat-core concept behind her chemistry tions, we would propose to use one
ing for medical devices. Polymerixis to build polymers designed to de- of our formulations designed to sur-
has expanded the focus to a familygrade by incorporating ester, anhy- face erode between 30 to 90 days,
of potentially more potent anti-dride, and/or amide bonds into the the usual window people are looking
inflammatory materials, the Poly-polymer backbone. These bonds are for with this type of application,” says
NSAIDs. A secondary platform withindegraded in the body either by enzy- Letton. The polymer breaks down
consistently, releasing drug from thematic activity or hydrolysis. the PolyNSAID family is its PolyDF
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device surface, avoiding initial spikes, a drug going off-patent, it becomes None of their polymers are in hu-
a wonderful business proposition toburst effect, unintended bolus dos- man studies yet, although animal
turn it into a polymer so you caning, and other toxicity concerns. It studies have been conducted for
enter other markets.”eventually degrades completely. Ex- several projects. Polymerix does
“With depot formulations of Poly-plains Letton, “Our leading polymers have a $26 million development col-
NSAIDs, we are looking at treatmentnow are polyanhydride-based, so laboration with an unnamed partner
of chronic pain conditions, like ar-they break down by hydrolysis and for noninflammatory coatings for
thritis,” says Hazelwood. “We areenzymatic action. We have created vascular stents and grafts. They
seeking to improve pain manage-chemistry that allows for precise hope to initiate human studies with
ment long term in a more controlledcontrol over the structure of our this product soon, with possible com-
manner because we can get con-polymers and regulates the rate of mercial availability within three years.
trolled release of polymer and miti-degradation.” They also have potential partners in
gate the need for multiple injections.”Design Flexibility and orthopedics and wound care man-
Longer term, Polymerix hopes to re-Lipophilic Materials agement. “We are at the point where
formulate other drug classes, likeAnother advantage of the Polymerix we would like more partners to get
oncology therapeutics, into depot for-approach is that more drug can be the technology into the market
mulations, thereby providing highlyloaded onto the device surface. “The quickly,” says Letton.
site-specific therapy without harmrest of the industry is able to load
Chemistry & Biology invites yourto normal tissue.about 30%–40% drug by weight
comments on this topic. PleaseThe company is poised to use theironto a polymer-coated medical de-
write to the editors at chembiol@computational chemistry tools tovice,” says Hazelwood, “but our sys-
cell.com.help other companies reformulatetem lets us coat up to 95% drug by
existing drugs into polymers. “Some-weight.” Once coated, the polymer Alice A. McCarthy is a freelance scienceone can come to us and give us areleases from the surface according writer based in Gloucester, MA (alice@set of requirements, and we will beto the design requirements of the alicemccarthy.com).
able to design in silico a set of poly-device. “Design flexibility is a funda-
mers to meet that objective,” saysmental strength of the technology,”
Letton. “That is going to be a verysays Letton. “We can make these
strong opportunity for anyone inter-
PolyNSAIDs degrade in 2 days, 2
ested in rapid deployment to
hours, 2 years, or more. And after
market.”
the drug is delivered, no polymer Existing Therapies
remains.” A key advantage of Polymerix’s
Polymerix also hopes to gain an technology platforms is that the
advantage by providing polymers company is presently focused on
that can solubilize highly in insolu- using existing drugs. “Most compa-
ble drugs. Says Letton, “Many new nies are involved in drug discovery
drugs coming out these days are and developing new materials, and
highly insoluble.” Adds Hazelwood, those timelines are very long,” says
“Drugs have to be able to distribute Letton. “We work with existing drugs
in the body to be useful. Since we with known toxicity and regulatory
can handle these compounds well, profiles. We expect that 70%–80%
we can breathe new life into drugs of our business will remain focused
in a depot delivery form that might on working with existing drugs.”
otherwise have poor pharmacologi- Polymerix’s leading indications
cal characteristics.” are focused on NSAIDS, since man-
Depot Drug Formulation aging inflammation is one of the
Polymerix is pursuing a technology most universal issues throughout
focused on creating polymer mi- the biomedical community. “And our
crosphere pharmaceutical products. technology is a perfect platform for
“This would be a depot formulation,” combined medications,” declares
says Letton. Drugs delivered sys- Letton. “This will lead us into appli-
temically may have low toxicity cations best served by multiple drug
thresholds. “But if you take that drug release.” Envision a disease indica-
and turn it into a microsphere depot tion requiring an NSAID with an anti-
polymer formulation, you can deliver proliferative, or an antiproliferative
it by injection locally, avoid systemic with an immunomodulator. “So many
toxicities, and improve efficacy,” ex- areas of medicine are suggesting that
lains Letton. In addition, it provides incremental improvement from drug
an advantage for pharmaceutical cocktails is the way to more effective
companies focused on product life therapies, rather than a single block-
cycle management. “This will be a buster,” says Letton. “With our tech-
new platform to extend the life cycle nology, you can achieve multiple
controlled dosing.”of a drug,” says Letton. “If you have
